- Home
- GIGM vs IMNN Comparison
GIGM vs IMNN Comparison
Compare GIGM & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- IMNN
- Stock Information
- Founded
- GIGM 1998
- IMNN 1982
- Country
- GIGM Taiwan
- IMNN United States
- Employees
- GIGM N/A
- IMNN N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- IMNN Health Care
- Exchange
- GIGM Nasdaq
- IMNN Nasdaq
- Market Cap
- GIGM 17.0M
- IMNN 12.1M
- IPO Year
- GIGM 2000
- IMNN 1985
- Fundamental
- Price
- GIGM $1.86
- IMNN $5.58
- Analyst Decision
- GIGM
- IMNN Buy
- Analyst Count
- GIGM 0
- IMNN 2
- Target Price
- GIGM N/A
- IMNN $182.61
- AVG Volume (30 Days)
- GIGM 23.8K
- IMNN 55.0K
- Earning Date
- GIGM 10-29-2025
- IMNN 11-06-2025
- Dividend Yield
- GIGM N/A
- IMNN N/A
- EPS Growth
- GIGM N/A
- IMNN N/A
- EPS
- GIGM N/A
- IMNN N/A
- Revenue
- GIGM $3,250,000.00
- IMNN N/A
- Revenue This Year
- GIGM N/A
- IMNN N/A
- Revenue Next Year
- GIGM N/A
- IMNN N/A
- P/E Ratio
- GIGM N/A
- IMNN N/A
- Revenue Growth
- GIGM N/A
- IMNN N/A
- 52 Week Low
- GIGM $1.30
- IMNN $4.83
- 52 Week High
- GIGM $1.89
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- GIGM 73.25
- IMNN 34.42
- Support Level
- GIGM $1.61
- IMNN $5.53
- Resistance Level
- GIGM $1.87
- IMNN $5.89
- Average True Range (ATR)
- GIGM 0.09
- IMNN 0.32
- MACD
- GIGM 0.03
- IMNN 0.06
- Stochastic Oscillator
- GIGM 92.88
- IMNN 8.71
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).